前列腺癌激素治疗相关间质性肺病的FAERS不良事件分析
结果显示ILD事件与nilutamide、flutamide、bicalutamide、goserelin、degarelix和apalutamide显著相关,且78.68%的ILD事件发生在激素治疗第一年内,日本人群病例占比高。
要点
- 激素治疗组ILD事件与nilutamide、flutamide、bicalutamide、goserelin、degarelix和apalutamide显著相关。
- 78.68%的ILD事件发生在激素治疗开始后第一年内,需重点监测。
- 日本人群激素治疗组ILD事件报告较多,应关注种族差异。
核心结论
- 基于FAERS药物警戒分析,激素治疗药物(bicalutamide、flutamide、nilutamide、goserelin、degarelix和apalutamide)与ILD事件的关联不应忽视,尤其在日本人群中。
研究设计与样本
- 采用报告比值比(ROR)这种不相称性分析方法检测ILD事件与目标药物的关联。
主要发现
- 激素治疗组628例ILD事件中,394例(62.74%)来自日本。
- 78.68%的ILD事件发生在激素治疗开始后第一年内。
- 不相称性分析显示ILD事件与nilutamide、flutamide、bicalutamide、goserelin、degarelix和apalutamide显著相关,ROR(95%CI)分别为32.14(11.03-93.63)、9.93(3.62-27.21)、8.19(6.01-11.16)、3.74(2.61-5.37)、2.41(1.55-3.75)和1.94(1.01-3.75)。
临床怎么用
- 前列腺癌患者接受上述激素治疗药物时应监测肺功能,尤其是用药后第一年内。
- 对日本人群使用激素治疗药物时需特别关注ILD风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate interstitial lung disease (ILD) in men with prostate cancer receiving hormone therapy. METHODS: We gathered cases diagnosed with prostate cancer based on the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database from 2004 to 2020. We divided the included cases into 3 groups based on the primary suspected drugs: a hormone therapy group, a positive control group (taxanes), and a negative control group. We employed reporting odds ratio, a disproportionality method, to detect the association between ILD events and target drugs. RESULTS: We finally included a total of 85 403 cases, 69 894 cases (628 ILD event cases) in the hormone therapy group, 2302 cases (158 ILD event cases) in the positive control group and 13 207 cases (72 ILD event cases) in the negative control group. There were 394 ILD event cases (62.74%) in the hormone therapy group in Japan; 78.68% of the ILD events occurred within the first year after hormone treatment. Disproportionality analysis indicated that ILD events were significantly associated with nilutamide, flutamide, bicalutamide, goserelin, degarelix and apalutamide; the reporting odds ratios (95% confidence interval) were 32.14 (11.03-93.63), 9.93 (3.62-27.21), 8.19 (6.01-11.16), 3.74 (2.61-5.37), 2.41 (1.55-3.75) and 1.94 (1.01-3.75), respectively. CONCLUSION: Based on this FAERS pharmacovigilance analysis, the association between ILD events and hormone therapy drugs, including bicalutamide, flutamide, nilutamide, goserelin, degarelix and apalutamide, should not be ignored, especially in the Japanese population. Lung function of prostate cancer patients should be monitored when receiving the hormone therapy drugs mentioned above, especially for the first year post medication.
引用
- Wu B, Shen P, Yin X, et al. Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System. Br J Clin Pharmacol. 2022. PMID: 35349180. doi:10.1111/bcp.15336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。